Accentia amends license with Mayo Clinic to develop over-the-counter sinusitis nasal sprays

By E. Janene Geiss

Philadelphia, Aug. 28 - Accentia Biopharmaceuticals, Inc. said Monday that it has amended its license with the Mayo Foundation for Medical Research and Education, granting Accentia an exclusive worldwide license to all non-prescription products that are intended to treat symptoms associated with chronic sinusitis by suppressing non-invasive fungi in the mucus of patients.

The amendment also grants Accentia the right to proceed with commercialization of a first product, according to a company news release.

Accentia said it previously obtained a worldwide exclusive license from the Mayo Clinic for SinuNase, whose active ingredient is the prescription antifungal amphotericin B.

The company said it is developing SinuNase as a prescription intranasal formulation for moderate to severe cases of chronic sinusitis. Under an Investigational New Drug application, Accentia said it received fast-track status for SinuNase from the Food and Drug Administration and is starting phase 3 clinical trials in patients with chronic sinusitis refractory to surgery.

Accentia is a Tampa, Fla., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.